Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.
Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.
复制标题
DOI：
10.1097/jcp.0b013e3181dbfd04
复制
发表时间：
2010-06
影响因子：
2.9
通讯作者：
Rush AJ
中科院分区：
文献类型：
--
作者：
Warden D;Trivedi MH;Wisniewski SR;Kurian B;Zisook S;Kornstein SG;Friedman ES;Miyahara S;Leuchter AF;Fava M;Rush AJ
选择性5-羟色胺再摄取抑制剂（SSRI）治疗期间的不良事件频繁发生，可能导致提前停药。如果损耗与副作用的早期恶化或副作用的频率、强度或负担相关，则可以将干预措施集中于发生这些事件的患者，以最大限度地保留药物。门诊参与者（n=265）与非精神病性重度抑郁症进入一个为期8周的试验与SSRI。在基线和第2周时，使用治疗后出现的事件的系统评估-系统调查评价特定副作用，并在第2周时使用副作用的频率、强度和负担评级全面评估副作用。停药定义为在第2周后但在第8周前离开治疗的受试者。没有特定的第2周副作用，无论是治疗后出现的还是强度恶化的，与损耗独立相关。第2周时副作用频率、强度或负担的总体评分也与随后的损耗无关。第2周的总体评分和特定副作用均与SSRI治疗期间的患者流失无关。其他因素似乎有助于患者决定继续治疗。
Adverse events during selective serotonin reuptake inhibitor (SSRI) treatment are frequent and may lead to premature treatment discontinuation. If attrition is associated with early worsening of side effects or the frequency, intensity, or burden of side effects, interventions to maximize retention could be focused on patients with these events. Outpatient participants (n=265) with nonpsychotic major depressive disorder entered an 8-week trial with an SSRI. At baseline and week 2, specific side effects were evaluated with the Systematic Assessment for Treatment Emergent Events – Systematic Inquiry, and at week 2 the Frequency, Intensity, and Burden of Side Effects Rating globally assessed side effects. Attrition was defined by those participants who left treatment after week 2 but before week 8. No specific week 2 side effect, either treatment emergent or with worsening intensity, was independently associated with attrition. Global ratings of side effect frequency, intensity, or burden at week 2 were also not associated with subsequent attrition. Neither global ratings nor specific side effects at week 2 were related to patient attrition during SSRI treatment. Other factors appear to contribute to patient decisions about continuing with treatment.